SCHEMBL265706

SCHEMBL265706

CCOC(=O)c1c(NC(=O)c2cccc(CN(CC(C)O)CC(C)O)c2)sc2c1CCC2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
TP53 P04637 3/20 0.61
CNR2 P34972 3/20 0.60
PDE4D Q08499 1/20 0.59
HPGD P15428 5/20 0.58
HSD17B10 Q99714 5/20 0.58
NPSR1 Q6W5P4 4/20 0.58
KDM4E B2RXH2 4/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
ALDH1A1 P00352 3/20 0.57
GAA P10253 1/20 0.57
MAPK1 P28482 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
USP2 O75604 2/20 0.56
ALOX15 P16050 1/20 0.56
PTGER2 P43116 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TSHR P16473 2/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266625 0.88 MEN1 (0.55) MAPTTP53HPGDNPSR1KDM4E
SCHEMBL267472 0.85 MAPT (0.67) MAPTTP53CNR2PDE4DHPGD
SCHEMBL268761 0.83 CNR2 (0.70) MAPTTP53CNR2PDE4DHPGD
SCHEMBL266185 0.82 MAPT (0.59) MAPTTP53CNR2PDE4DHPGD
SCHEMBL267495 0.81 SLC34A2 (0.50) MAPTTP53MEN1KMT2A
SCHEMBL267494 0.81 SLC34A2 (0.50) MAPTTP53MEN1KMT2A
SCHEMBL267586 0.81 SLC34A2 (0.51) MAPTTP53MEN1KMT2A
SCHEMBL267587 0.81 SLC34A2 (0.51) MAPTTP53MEN1KMT2A
SCHEMBL8290510 0.81 MAPT (0.77) MAPTTP53CNR2PDE4DHPGD
SCHEMBL265899 0.80 MAPT (0.61) MAPTTP53CNR2PDE4DHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885TP53 2556/4885CNR2 1412/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885TP53 2188/4885CNR2 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.